NASDAQ : BDRX
Biodexa Pharmaceuticals Plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 3.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 441.21K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 441,211 |
| Enterprise Value | -3.84M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 128,633 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 0.05% |
| Float | 115,517 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.03 |
| P/TBV Ratio | 0.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.41 |
| Quick Ratio | 2.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.15 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.00% |
| Return on Assets (ROA) | -40.11% |
| Return on Invested Capital (ROIC) | -138.48% |
| Return on Capital Employed (ROCE) | -88.89% |
| Weighted Average Cost of Capital (WACC) | 11.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$533,127 |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 137,986 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -98.56% |
| 50-Day Moving Average | 5.58 |
| 200-Day Moving Average | 25.36 |
| Relative Strength Index (RSI) | 39.59 |
| Average Volume (20 Days) | 528,682 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 919,936 |
| Short Previous Month | 18,380 |
| Short % of Shares Out | 41.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -6.92M |
| Operating Income | -11.73M |
| Pretax Income | -5.73M |
| Net Income | -5.86M |
| EBITDA | -11.74M |
| EBIT | -11.73M |
| Earnings Per Share (EPS) | -$102.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.29M |
| Total Debt | n/a |
| Net Cash | 4.29M |
| Net Cash Per Share | $33.32 |
| Equity (Book Value) | 12.75M |
| Book Value Per Share | 136.76 |
| Working Capital | 5.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.24M |
| Capital Expenditures | -9,372 |
| Depreciation & Amortization | -10,710 |
| Net Borrowing | -705,548 |
| Free Cash Flow | -9.24M |
| FCF Per Share | -$71.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -2,988.48% |
| FCF Yield | -2,095.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |